ASX Penny Stocks Under A$600M Market Cap To Watch

Simply Wall St

The Australian stock market is experiencing a mixed performance, with local shares pulling back despite global indices climbing higher. As inflation data looms, investors are cautious, creating an intriguing backdrop for exploring potential opportunities in the penny stock space. While the term "penny stocks" may seem outdated, these smaller or less-established companies can still offer significant value when backed by strong financials and growth potential.

Top 10 Penny Stocks In Australia

NameShare PriceMarket CapRewards & Risks
Alfabs Australia (ASX:AAL)A$0.47A$134.7M✅ 4 ⚠️ 3 View Analysis >
Dusk Group (ASX:DSK)A$0.92A$57.29M✅ 4 ⚠️ 2 View Analysis >
IVE Group (ASX:IGL)A$2.81A$432.02M✅ 4 ⚠️ 3 View Analysis >
MotorCycle Holdings (ASX:MTO)A$3.87A$285.63M✅ 4 ⚠️ 2 View Analysis >
Pureprofile (ASX:PPL)A$0.043A$50.3M✅ 3 ⚠️ 1 View Analysis >
Veris (ASX:VRS)A$0.077A$40.56M✅ 3 ⚠️ 2 View Analysis >
West African Resources (ASX:WAF)A$3.04A$3.47B✅ 4 ⚠️ 2 View Analysis >
Fleetwood (ASX:FWD)A$3.08A$284.39M✅ 3 ⚠️ 2 View Analysis >
Perenti (ASX:PRN)A$2.73A$2.57B✅ 3 ⚠️ 3 View Analysis >
Clover (ASX:CLV)A$0.63A$105.21M✅ 3 ⚠️ 2 View Analysis >

Click here to see the full list of 418 stocks from our ASX Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Aeris Resources (ASX:AIS)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Aeris Resources Limited is an Australian company engaged in the exploration, production, and sale of precious metals, with a market cap of A$534.28 million.

Operations: The company's revenue is primarily generated from its operations at Tritton (A$303.36 million), Cracow (A$197.51 million), North Qld (A$75.27 million), and Jaguar (A$0.92 million).

Market Cap: A$534.28M

Aeris Resources, with a market cap of A$534.28 million, has shown significant financial improvement by becoming profitable this year, reporting a net income of A$45.2 million compared to a loss the previous year. The company's debt management is commendable, with its debt-to-equity ratio decreasing significantly over five years and operating cash flow covering debt well. However, short-term assets do not cover liabilities fully, which could pose liquidity challenges. Despite these concerns, Aeris trades at good value compared to peers and industry standards and has stable weekly volatility at 12%, suggesting relative market stability for investors interested in penny stocks.

ASX:AIS Financial Position Analysis as at Oct 2025

Coast Entertainment Holdings (ASX:CEH)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Coast Entertainment Holdings Limited is involved in the investment, ownership, and operation of leisure and entertainment businesses in Australia, with a market cap of A$182.62 million.

Operations: The company generates revenue from its Theme Parks & Attractions segment, amounting to A$96.40 million.

Market Cap: A$182.62M

Coast Entertainment Holdings, with a market cap of A$182.62 million, has faced challenges as it reported a net loss of A$0.112 million for the fiscal year ending June 2025, down from a net income of A$2.62 million the previous year. Despite being unprofitable, Coast Entertainment has reduced its losses by 57.9% annually over five years and maintains no debt, enhancing financial stability. The company completed a significant share buyback program in August 2025, repurchasing over 10% of its shares for A$17.7 million, potentially signaling management's confidence in future prospects amidst current volatility and limited cash runway under one year.

ASX:CEH Financial Position Analysis as at Oct 2025

PharmX Technologies (ASX:PHX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: PharmX Technologies Limited operates as a technology and software development company in Australia, with a market cap of A$101.92 million.

Operations: PharmX Technologies generates revenue from its Health Services segment, amounting to A$7.53 million.

Market Cap: A$101.92M

PharmX Technologies, with a market cap of A$101.92 million, reported sales of A$7.32 million for the fiscal year ending June 2025 but remains unprofitable with a net loss of A$0.264 million. Despite no debt and short-term assets exceeding liabilities, the company's management team has an average tenure of just 1.9 years, indicating inexperience. Recent board changes include Alexander Mellis's appointment as a Non-Executive Director following Dennis Bastas's resignation due to administrative oversights related to ASX Listing Rules compliance. PharmX's share price has been highly volatile recently, reflecting broader challenges within its operational landscape.

ASX:PHX Financial Position Analysis as at Oct 2025

Make It Happen

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Aeris Resources might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com